Advanced search
Publication Cover
Hospital Practice Volume 41, 2013 - Issue 2
Submit an article Journal homepage
243
Views
12
CrossRef citations to date
0
Altmetric
Clinical Features

A Comparative Trial of Anti-Factor Xa Levels Versus the Activated Partial Thromboplastin Time for Heparin Monitoring

Jeremy W. Vandiver Clinical Assistant Professor of Pharmacy Practice, University of Wyoming, School of Pharmacy, Laramie, WYCorrespondence[email protected]
, PharmD, BCPS &
Thomas G. Vondracek Clinical Pharmacy Specialist, Exempla Saint Joseph Hospital, Denver, CO
, PharmD, BCPS
Pages 16-24 | Published online: 13 Mar 2015

References

  • . Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141( 2 suppl):e24S–e43S
  • . Olson JD, Arkin CF, Brandt JT, . College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin. Arch Pathol Lab Med. 1998;122(9):782–798
  • . Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med. 1996;156(15):1677–1681
  • . Anand SS, Bates S, Ginsberg JS, . Recurrent venous thrombosis and heparin therapy. An evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med. 1999;159(17):2029–2032
  • . Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96(5):547–552
  • . Spinler SA, Wittkovsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother. 2005;39(7–8):1275–1285
  • . Rosenberg AF, Zumberg M, Taylor L, LeClaire A, Harris N. The use of anti—Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract. 2010;23(3):210–216
  • . Kitchens CS. To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemost. 2005;3(12):2607–2611
  • . Hirsh J, Raschke R, Warkentin T, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995; 108( 4 suppl):258S–275S
  • . Valenstein PN, Walsh MK, Meier F; College of American Pathologists. Heparin monitoring and patient safety: a College of American Pathology Q-probes study of 3431 patients at 140 institutions. Arch Pathol Lab Med. 2004;128(4):397–402
  • . Lehman CM, Frank EL. Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti—Xa assay? Lab Medicine. 2009;40:687–690
  • . Ignjatovic V, Summerhayes R, Gan A, . Monitoring unfractionated heparin (UFH) therapy: which anti—factor Xa assay is appropriate? Thromb Res. 2007;120(3):347–351
  • . Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546–558
  • . Levine MN, Hirsh J, Gent M, . A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49–56
  • . Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with activated partial thromboplastin time. Pharmacotherapy. 1999;19(6):760–766
  • . Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in anti—Xa monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother. 2011;45(7–8):861–868
  • . Smythe MA, Mattson JC, Koerber JM. The heparin anti—Xa therapeutic range: are we there yet? [editorial]. Chest. 2002;121(1):303–304

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.